Insmed to Present at September Investor Conferences, Announces Management Participation

Insmed Incorporated announced that management will present at the Wells Fargo 2025 Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference in September. The presentations will be webcast live and available on the company's website. Insmed is a people-first global biopharmaceutical company developing therapies for serious diseases.

Insmed Incorporated, a global biopharmaceutical company, has announced that its management team will present at the Wells Fargo 2025 Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference in September. The presentations will be webcast live and available on the company's website. Insmed focuses on developing therapies for serious diseases, with a particular emphasis on respiratory conditions.

The company has a robust pipeline of respiratory therapies, including brensocatib, a small molecule oral inhibitor of dipeptidyl peptidase 1 (DPP1), which has shown consistent efficacy and safety across multiple subgroups in the ASPEN study [1]. The study demonstrated that brensocatib reduced pulmonary exacerbations, prolonged time to first exacerbation, and reduced lung function decline compared to placebo, with a similar safety profile across various patient types.

Additionally, Insmed presented data on treprostinil palmitil inhalation powder (TPIP) and ARIKAYCE® (amikacin liposome inhalation suspension) at the American Thoracic Society (ATS) 2025 International Conference. TPIP is being evaluated for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), while ARIKAYCE is a novel, inhaled formulation of amikacin used for refractory Mycobacterium avium complex (MAC) lung disease.

The company's commitment to advancing research and improving patient outcomes was evident in its presentations at the ATS conference. The breadth and depth of Insmed's scientific contributions reflect its dedication to transforming care for patients with serious diseases.

References:
[1] https://investor.insmed.com/2025-05-21-Brensocatib-Shows-Consistent-Efficacy-and-Safety-Across-Three-Prespecified-Subgroups-in-New-Data-from-Landmark-ASPEN-Study